Literature DB >> 2417678

Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?

J K Patel, T Nemoto, M Vezeridis, N Petrelli, O Suh, T L Dao.   

Abstract

A retrospective review of 483 women who had metastatic breast cancer and were treated between 1942 and 1975 was carried out to examine the effects of improving and aggressive palliative modalities on patient survival. There was a steady increase in the proportion of patients treated by chemotherapy and/or hormonal ablative therapy. Additive hormonal therapy, irradiation, and surgery for palliation decreased in frequency during the same period. Survival time from the first recurrence did not appear to increase in these patients over the period of this study. In spite of increasingly sophisticated palliative therapies, the survival time of patients with metastasis did not appear to be significantly prolonged.

Entities:  

Mesh:

Year:  1986        PMID: 2417678     DOI: 10.1002/1097-0142(19860201)57:3<567::aid-cncr2820570328>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Recent developments in treatment stratification for metastatic breast cancer.

Authors:  Sarah Barton; Charles Swanton
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

2.  No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy.

Authors:  E Petru; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 3.  Response to treatment of breast cancer.

Authors:  J L Berenberg
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

Review 4.  Postmenopausal breast cancer. Drug therapy in the 1990s.

Authors:  C I Falkson; G Falkson; H C Falkson
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

5.  Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.

Authors:  C J Twelves; N A Dobbs; M Aldhous; P G Harper; R D Rubens; M A Richards
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Survival effect of systemic therapy on patients developing metastatic breast carcinoma.

Authors:  J Rouesse; S Friedman; I Guash-Jordan; K Hacene; M Brunet
Journal:  Breast Cancer Res Treat       Date:  1990-01       Impact factor: 4.872

7.  Treatment of the terminal stages of breast cancer.

Authors:  K Holli; M Hakama
Journal:  BMJ       Date:  1989-01-07

8.  Does chemotherapy improve survival in advanced breast cancer? A statistical overview.

Authors:  R P A'Hern; S R Ebbs; M B Baum
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

9.  Modulation of cytosolic sexual steroid receptors in autochthonous methylnitrosourea-induced rat mammary carcinoma following application of 2-chloroethylnitrosocarbamoyl-L-alanine linked to oestradiol or dihydrotestosterone.

Authors:  R Corr; M R Berger; B Betsch; J A Floride; H P Brix; D Schmähl
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

10.  Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?

Authors:  A R Dixon; L Jackson; S Y Chan; R A Badley; R W Blamey
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.